Incannex Meets with FDA in Pre-IND Meeting for Sleep Apnea Drug Candidate
Incannex characterized the pre-investigational new drug application (pre-IND) meeting about IHL-42X as “highly constructive.”
Incannex characterized the pre-investigational new drug application (pre-IND) meeting about IHL-42X as “highly constructive.”
'The Sunosi acquisition marks the transformation of Axsome into a commercial neuroscience company and reflects our commitment to the millions of people living with serious neurologic and psychiatric conditions.'
Management responsibility and oversight have been strengthened with organizational changes implemented in Philips Respironics.
Children with Down syndrome and sleep apnea are more likely to experience aggressive behavior, brain fogging, and a loss of nearly 10 points in IQ compared to those without.
Read MoreAdvances in home sleep testing may chip away at the number of people who remain undiagnosed while capturing a more accurate calculation of the apnea hypopnea index.
Read MoreDiagnosing and treating sleep apnea may make driving safer for older adults.
Read MoreResearchers think they’ve found a drug that might ease sleep apnea.
Read MoreA new investigation found that rapid eye movement obstructive sleep apnea (REM-OSA) was associated with early signs of atherosclerosis, though the association remained unclear.
Read MoreSulthiame, a carbonic anhydrase inhibitor, lowered obstructive sleep apnea by more than 20 events/hour, a notable decline for a drug trial.
Read MoreWhile those with sleep apnea did have more severe outcomes with COVID-19, they were not at a higher risk for contracting the virus.
Read MoreThere has been increasing interest in the use of sleep apnea apps to aid in the detection and treatment of OSA.
Read MoreThe acquisition of Sunosi adds a high-potential commercial asset to Axsome’s late-stage neuroscience portfolio.
Read MoreMagdy Younes and associates have revealed new insights into clinical symptoms of sleep disorders found in sleep architecture.
Read MorePreviously named SomNyx, the appliance will be rebranded as D-SAD|Myo within Panthera Dental’s digital sleep appliance range.
Read MoreResearchers from the University of Missouri School of Medicine have found that untreated sleep apnea accelerates the biological aging process and that appropriate treatment can slow or possibly reverse the trend.
Read MoreRest Assure is a smart oral appliance that transfers efficacy and adherence data to cloud-based servers, allowing physicians and dentists to see the results.
Read MoreThe randomized controlled trial seeks to demonstrate the safety and effectiveness of the LivaNova aura6000 System for moderate to severe OSA.
Read MoreNeurostimulators don’t have decades of patient data like CPAP, but Inspire and remedē’s 1- and 5-year outcome studies show sustained benefits.
Read More